Implantable devices that deliver electrical impulses to the dorsal columns of the spinal cord (Spinal Cord Stimulation- SCS) and peripheral nerves (Peripheral Nerve Stimulation- PNS) have become an important non-pharmacologic, non-opioid treatment option for intractable chronic pain. While multiple clinical trials have confirmed the effectiveness for Chronic Persistent Post Surgical pain (CPPS), complex regional pain syndrome (CRPS), and other conditions, the short- and long-term success of the therapy depends on proper patient selection. Chronic pain multidimensional with physical, environmental, and psychological components should be fully evaluated to improve therapeutic outcomes. To facilitate comprehensive patient assessments and to provide access for VA sites without needed expertise, the VHA Pain Management, Opioid Safety and PDMP (PMOP) program designed a national Telehealth program, TelePain Evaluation for Neuromodulation Treatment (TENT). This program aims to address access to standardized, high-quality, and comprehensive SCS assessment for Veterans with intractable chronic pain. The TENT program provides comprehensive evaluations including chart review, telehealth visits, and consultations completed by a team of pain physicians and psychologists. After individual, virtual patient evaluations, the clinical team meets to consult on findings and recommendations which may include additional medical and/or psychological interventions to consider before or in conjunction with SCS. These recommendations are communicated to the patient via a shared medical appointment with TENT clinicians. Following this visit, the referring provider(s) are notified of the recommendations and have access to all evaluative reports. The TENT program care pathway went through a design phase in 2024 and an implementation phase in 2025 within VISN10. Between February and October of 2025, the TENT program executed over 35 interfacility consults (IFCs). The percentage of IFCs currently equals 22% (8/36) and 78% (28/36) for those originating from VA facilities and community care pain clinicians, respectively. Patient recommendations to proceed with neuromodulation therapy currently equals 44% (16/36) of consults. When applicable, Veterans with contraindications were provided feedback on how to improve their candidacy and when and under what conditions to reconsider neuromodulation. Building a true national program for preimplantation comprehensive evaluation for neuromodulation with a goal of identifying contraindications or psychological factors that might complicate or render the treatment ineffective has presented challenges. First, patients experience technology issues with video to home visits; patient-side sites often have limited personnel to address, test, and track these patient issues. Second, systemic issues have arisen involving cumbersome steps to attain national remote care delivery guidelines. The future presents issues relate to working in dual EMRs and unclear IFC processes in new EMR. Additional systemic issues relate to complicated administrative burden on clinic design and scheduling between the spoke and hub sites. Despite challenges preliminary data suggest the TENT program may: a) improve access to new technologies for treatment of chronic pain; b) improve patient selection to increase therapeutic effectiveness; c) provide a cost-effective care pathway by reducing the need for local expertise in small to medium medical centers. The TENT program capitalizes on VHA’s capacity for and focus on telehealth services to provide access to specialized care clinical services.